Clinical response in relation to mutational status at start of study and at relapse
| Patient ID . | Mutation at start . | Best response . | PCR negative* . | TTR† . | Mutation at relapse . |
|---|---|---|---|---|---|
| 1 | P-loop | CR | Yes | 683 | G250E |
| 2 | E255K | CR | No | 147 | E255K |
| 3 | P-loop | CR | Yes | 450 | G250E |
| 4 | T315I | CR | Yes | 319 | T315I |
| 5 | F317L | CR | No | 411 | F317L |
| 6 | T315I | CR | Yes | 102 | T315I |
| 7 | E255V | CR | No | 745 | E255V |
| 8 | P-loop | Failure | No | 29 | Y253H |
| 9 | T315I | Failure | No | 53 | T315I |
| 10 | P-loop | CR | No | 105 | F311I |
| 11 | P-loop | CR | Yes | 689 | E355G |
| Patient ID . | Mutation at start . | Best response . | PCR negative* . | TTR† . | Mutation at relapse . |
|---|---|---|---|---|---|
| 1 | P-loop | CR | Yes | 683 | G250E |
| 2 | E255K | CR | No | 147 | E255K |
| 3 | P-loop | CR | Yes | 450 | G250E |
| 4 | T315I | CR | Yes | 319 | T315I |
| 5 | F317L | CR | No | 411 | F317L |
| 6 | T315I | CR | Yes | 102 | T315I |
| 7 | E255V | CR | No | 745 | E255V |
| 8 | P-loop | Failure | No | 29 | Y253H |
| 9 | T315I | Failure | No | 53 | T315I |
| 10 | P-loop | CR | No | 105 | F311I |
| 11 | P-loop | CR | Yes | 689 | E355G |
Mutations at start of treatment were determined by D-HPLC and ASO-PCR in case of the T315I and E255K mutations, and by D-HPLC and sequencing at relapse.
PCR negative reflects undetectability of BCR-ABL transcripts by both quantitative PCR and nested PCR.
TTR, Time to relapse calculated from the diagnosis of a CR; in the 2 patients who failed treatment, values indicate time from diagnosis to disease progression and discontinuation of study treatment.